Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH) priced an upsized underwritten public offering of 7,313,582 common shares at $81.00 per share and pre-funded warrants for 402,468 shares at $80.999, with aggregate gross proceeds of approximately $625 million before fees.

The offering is expected to close on March 12, 2026, and underwriters have a 30-day option to purchase up to an additional 1,157,407 shares. Net proceeds will fund clinical/preclinical programs, commercial readiness, working capital, and general corporate purposes.

Positive

• Raised approximately $625 million gross proceeds
• Offered 7.31 million common shares at $81.00 per share
• Included 402,468 pre-funded warrants exercisable immediately
• Underwriters have a 30-day option for 1,157,407 additional shares
• Proceeds earmarked for clinical, preclinical, and commercial readiness

Negative

• Potential dilution from 7.31 million shares and warrants
• Additional dilution risk if underwriters exercise 1,157,407 option
• Gross proceeds subject to underwriting discounts, commissions, and fees

News Market Reaction – DNTH

-1.24% 2.4x vol

26 alerts

-1.24% News Effect

+5.1% Peak in 5 hr 43 min

-$49M Valuation Impact

$3.87B Market Cap

2.4x Rel. Volume

On the day this news was published, DNTH declined 1.24%, reflecting a mild negative market reaction. Argus tracked a peak move of +5.1% during that session. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $49M from the company's valuation, bringing the market cap to $3.87B at that time. Trading volume was elevated at 2.4x the daily average, suggesting increased selling activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Gross proceeds: $625 million Common shares offered: 7,313,582 shares Offering price: $81.00 per share +5 more

8 metrics

Gross proceeds $625 million Aggregate gross proceeds from upsized underwritten offering, before fees and expenses

Common shares offered 7,313,582 shares Shares of common stock offered in the underwritten deal

Offering price $81.00 per share Public offering price per share of common stock

Pre-funded warrants 402,468 warrants Pre-funded warrants offered in lieu of common stock to certain investors

Pre-funded warrant price $80.999 per warrant Public offering price per pre-funded warrant

Warrant exercise price $0.001 per share Exercise price for shares underlying pre-funded warrants

Underwriters’ option shares 1,157,407 shares Additional common shares subject to 30-day underwriters’ option

Underwriters’ option period 30 days Duration of option to purchase additional common shares

Market Reality Check

Price: $77.86 Vol: Volume 2,323,659 is 2.37x...

high vol

$77.86 Last Close

Volume Volume 2,323,659 is 2.37x the 20-day average of 981,953, indicating elevated trading interest ahead of the offering. high

Technical Shares trade near a 52-week high of 86.97 and remain above the 200-day MA at 34.58 heading into this upsized deal.

Peers on Argus

DNTH gained 9.71% while peers showed mixed, mostly modest moves (e.g., AMLX +4.6...

DNTH gained 9.71% while peers showed mixed, mostly modest moves (e.g., AMLX +4.68%, NTLA -1.25%). No peers appeared in the momentum scanner, suggesting the reaction was company-specific rather than a broad biotech move.

Previous Offering Reports

3 past events · Latest: Sep 11 (Negative)

Same Type Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Sep 11	Offering closing	Negative	-1.9%	Closed upsized $288M underwritten offering including full option exercise.
Sep 09	Offering pricing	Negative	+6.5%	Priced upsized $251M offering of stock and pre-funded warrants.
Sep 08	Offering proposed	Negative	+11.9%	Proposed $150M underwritten offering plus $22.5M overallotment option.

Pattern Detected

Past equity offerings often saw mixed reactions, with one modest decline and two notable gains, indicating investor responses to dilution have been inconsistent.

Recent Company History

Over the past year, Dianthus has repeatedly accessed the equity markets via underwritten offerings. In September 2025, it moved from a proposed $150 million deal to an upsized offering that ultimately raised about $288 million in gross proceeds, including full exercise of the underwriters’ option. Price reactions ranged from a -1.85% dip to double‑digit gains, showing that prior financings were sometimes embraced despite dilution, particularly when tied to pipeline and growth funding.

Historical Comparison

+5.5% avg move · In the past, DNTH’s offering-related headlines produced an average move of 5.52%. Today’s +9.71% gai...

offering

+5.5%

Average Historical Move offering

In the past, DNTH’s offering-related headlines produced an average move of 5.52%. Today’s +9.71% gain on another upsized equity deal sits above that typical reaction range.

Equity raises progressed from a proposed $150M deal in September 2025 to an upsized $288M closing, and now to a substantially larger $625M offering to further fund pipeline development and corporate needs.

Regulatory & Risk Context

Active S-3 Shelf · $600,000,000

Shelf Active

Active S-3 Shelf Registration 2026-01-28

$600,000,000 registered capacity

Dianthus has an effective Form S-3 shelf filed on 2026-01-28, registering up to $600,000,000 of securities. The current underwritten offering, including common stock and pre-funded warrants, is being conducted off this shelf, following a 424B5 prospectus supplement filed on 2026-03-09.

Market Pulse Summary

This announcement detailed an upsized underwritten offering raising about $625 million through commo...

Analysis

This announcement detailed an upsized underwritten offering raising about $625 million through common stock and pre-funded warrants priced around $81. It was conducted off an effective Form S-3 shelf, with a 30-day option on another 1,157,407 shares. Historically, similar Dianthus offerings have prompted mixed stock reactions. Investors monitoring this deal may focus on execution, use of proceeds across late‑stage programs, and any subsequent capital structure changes.

Key Terms

underwritten public offering, pre-funded warrants, shelf registration statement, form s-3, +2 more

6 terms

underwritten public offering financial

"announced the pricing of its previously announced upsized underwritten public offering of 7,313,582"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"The offering is being made pursuant to a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"pursuant to a shelf registration statement on Form S-3 relating to the securities that was previously filed"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

rule 462(b) regulatory

"a related registration statement that was filed with the SEC on March 10, 2026 pursuant to Rule 462(b)"

Rule 462(b) is an SEC provision that lets an issuer add more securities of the same class to an already-effective registration statement by filing a short post-effective amendment that becomes effective on filing, so the additional securities are immediately registered without redoing the full approval process. For investors this matters because it lets companies and underwriters expand an offering quickly—like adding extra seats to a sold-out show—changing supply and potential dilution that can affect the stock price.

prospectus supplement regulatory

"only by means of a written prospectus, including a prospectus supplement, forming a part of an effective"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. Not financial advice.

NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the pricing of its previously announced upsized underwritten public offering of 7,313,582 shares of its common stock at a public offering price per share of $81.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a public offering price of $80.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering are expected to be approximately $625 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Dianthus, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on March 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Dianthus has granted the underwriters a 30-day option to purchase up to an additional 1,157,407 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by Dianthus.

Dianthus intends to use the net proceeds from this offering to advance the Company’s clinical and preclinical development activities, commercial readiness activities as well as for working capital and general corporate purposes.

Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair are acting as joint book-running managers for the offering. LifeSci Capital is acting as Dianthus’ financial advisor.

The offering is being made pursuant to a shelf registration statement on Form S-3 relating to the securities that was previously filed with the Securities and Exchange Commission (“SEC”) and declared effective on January 30, 2026 and a related registration statement that was filed with the SEC on March 10, 2026 pursuant to Rule 462(b) under the Securities Act of 1933, as amended (and became automatically effective upon filing). This offering is being made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov, and, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding Dianthus’ expectations regarding the consummation of the offering, the satisfaction of customary closing conditions with respect to the offering and the potential value and clinical benefit of the Company’s product candidates. The words “opportunity,” “potential,” “milestones,” “runway,” “will,” “anticipate,” “achieve,” “near-term,” “catalysts,” “pursue,” “pipeline,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart and DNTH212 and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the development of claseprubart, DNTH212 or the Company’s other compounds may take longer and/or cost more than planned, that the Company or its partner may be unable to successfully complete the clinical development of the Company’s compounds, that the Company or its partner may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company's compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading "Risk Factors" included in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

How much did Dianthus (DNTH) raise in the March 2026 offering?

The offering is expected to raise approximately $625 million in gross proceeds. According to the company, this amount is before underwriting discounts, commissions and offering expenses, and excludes any additional shares sold under the underwriters’ 30-day option.

What securities did Dianthus (DNTH) sell in the upsized offering?

Dianthus sold 7,313,582 common shares and pre-funded warrants for 402,468 shares. According to the company, the pre-funded warrants are exercisable immediately at an exercise price of $0.001 per share.

When will the Dianthus (DNTH) offering close and are there additional share options?

The offering is expected to close on March 12, 2026, subject to customary conditions. According to the company, underwriters have a 30-day option to purchase up to 1,157,407 additional shares at the offering price.

How does Dianthus (DNTH) plan to use the net proceeds from the offering?

Net proceeds will fund clinical and preclinical development, commercial readiness, working capital, and general corporate purposes. According to the company, the funds are intended to advance its programs and support corporate operations.

Who are the lead managers for Dianthus (DNTH) March 2026 offering?

Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair acted as joint book-running managers. According to the company, LifeSci Capital served as financial advisor for the offering.